These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14567534)

  • 1. Analysis and results of the recombinant factor VIIa extended-use registry.
    Laffan M; O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy D; Smith OP
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S35-8. PubMed ID: 14567534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Novo Nordisk's clinical trial programme on NovoSeven.
    Dejgaard A
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S39-41. PubMed ID: 14567535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa (Novoseven) and the safety of treatment.
    Roberts HR
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
    Payne EM; Brett SJ; Laffan MA
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of recombinant factor VIIa.
    Roberts HR; Monroe DM; Hoffman M
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
    Mantzios G; Tsirigotis P; Pappa V; Spirou K; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Dervenoulas J
    Eur J Haematol; 2007 Feb; 78(2):173-4. PubMed ID: 17313564
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
    Raivio P; Suojaranta-Ylinen R; Kuitunen AH
    Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review.
    Grounds M
    Blood Rev; 2003 Sep; 17 Suppl 1():S11-21. PubMed ID: 14697209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial.
    Mayer SA; Brun NC; Broderick J; Davis SM; Diringer MN; Skolnick BE; Steiner T;
    Neurocrit Care; 2006; 4(3):206-14. PubMed ID: 16757825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
    Poon MC; Zotz R; Di Minno G; Abrams ZS; Knudsen JB; Laurian Y
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic interventions for the management of critical bleeding.
    Voils S
    Pharmacotherapy; 2007 Sep; 27(9 Pt 2):69S-84S. PubMed ID: 17723110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].
    Tanchev S; Pandurski F; Georgiev A; Gesheva Iu; Platikanov V; Dinov P
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():32-5. PubMed ID: 15518274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant FVIIa in the management of uncontrolled hemorrhage.
    O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy DF; Laffan MA; Smith OP
    Transfusion; 2003 Dec; 43(12):1711-6. PubMed ID: 14641868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant activated factor VII in the postanesthetic recovery unit: review of 16 cases].
    Etxániz Alvarez A; Pita Zapata E; Rama Maceiras P; Duro Tacón J; Pose Cambeiro P
    Rev Esp Anestesiol Reanim; 2006 Mar; 53(3):159-62. PubMed ID: 16671259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
    Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
    Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.